Last Update: Oct 28, 2024
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
ClinicalTrials.gov Identifier:
Novartis Reference Number:CHK02-02
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy Approximately 272 participants with eGFR ≥ 30 mL/min/1.73m^2 and with biopsy-proven IgAN
will be randomized to receive 600 mg Q2W BION-1301 or a matched placebo for 104 weeks. An
additional exploratory cohort, not included in the primary analysis, will be comprised of
approximately 20 participants (10 participants per arm) with biopsy-confirmed IgAN and
eGFR of ≥ 20 to < 30 mL/min/1.73 m^2. The exploratory cohort will be randomized using the
same schema as the primary cohort.

The primary objective of the study is to evaluate the effect of BION-1301 versus placebo
on proteinuria in adults with IgA nephropathy.

Participants will have assessments of safety and efficacy for 2.5 years (up to 134
weeks). To facilitate study participation over this time period, other visits may be
remote (away from study site) for participants who elect to self-administer the study
drug.

IgA Nephropathy, Immunoglobulin A Nephropathy
Phase3
Recruiting
292
Jul 27, 2023
Jun 07, 2028
All
18 Years - (Adult, Older Adult)

Interventions

Drug

BION-1301

BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
Drug

Placebo

Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.

Eligibility Criteria

Inclusion Criteria:

- Male and female participants aged ≥ 18 years at the time of signing the informed
consent form (ICF) prior to initiation of any study specific activities/procedures.

- Biopsy-proven IgAN diagnosed within the past 10 years prior to Screening, that, in
the opinion of the Investigator, is not due to secondary causes. A pseudonymized
copy of the report must be available for review by the Sponsor or designee prior to
randomization. If biopsy report within 10 years is not available, re-biopsy may be
permitted upon discussion with the Medical Monitor.

- eGFR ≥ 30 mL/min/1.73m^2 at Screening based on the 2021 CKD-EPI equation.

- Total urine protein ≥ 1.0 g/day and UPCR ≥ 0.7 g/g (700 mg/g), as measured from an
adequate 24-hour urine collection at Screening by a central laboratory.

- Stable on a maximally tolerated dose of ACEi/ARB for at least 12 weeks prior to
Screening unless intolerant to ACEi/ARB. May also be on a stable and well tolerated
dose of SGLT2i and/or ERAs/MRAs for at least 12 weeks prior to Screening for the
treatment of IgAN. Participants are expected to stay on the ACEi/ARB, SGLT2i and/or
the ERAs/MRAs for the duration of the study.

- Body mass index (BMI) between 18 and 40 kg/m^2.

- Screening weight of 45 to 150 kg.

- Men and women of childbearing potential (WOCBP; per Clinical Trials Facilitation and
Coordination Group [CTFG] 2020) must agree to follow protocol-specified
contraception guidance from Screening through approximately 5 half-lives (24 weeks)
after the final dose of study drug. Use of hormonal contraceptive agents must have
been initiated > 1 month prior to first dose of study drug.

- Provide written informed consent and be willing to comply with study visits and
procedures.

Exclusion Criteria:

- Secondary forms of IgAN as determined by the Investigator, in the setting of
systemic disorders, infections, autoimmune disorders or neoplasias.

- Diagnosis of IgA Vasculitis.

- Current or history of nephrotic syndrome.

- Average blood pressure > 150/90 mm Hg (systolic/diastolic) from 3 readings obtained
at the initial Screening visit. If blood pressure is too high, the 3 readings may be
repeated once within the Screening period if clinically appropriate as per the
Investigator.

- Clinical suspicion of IgAN with rapidly progressive glomerulonephritis (RPGN) based
on KDIGO guidelines

- Chronic Kidney Disease, either clinically suspected or based on biopsy, resulting
from any condition or another glomerulopathy/podocytopathy other than IgAN.

- History of Type 1 Diabetes.

- Participants with Type 2 diabetes are excluded if any of the following are present:

- Screening HbA1c (glycated hemoglobin) of > 8%.

- Evidence of diabetic changes on kidney biopsy, performed for any reason.

- History of diabetic microvascular disease (retinopathy, neuropathy,
nephropathy) and/or macrovascular disease (atherosclerotic heart disease,
peripheral vascular disease, cerebrovascular disease).

- Unstable anti-diabetic regimen:

- Prior exposure to any antibody directed against APRIL.

- History of a previous severe allergic reaction with generalized urticaria,
angioedema, or anaphylaxis, including a history of allergy or hypersensitivity to
any component of BION-1301, or history of severe hypersensitivity reaction to any
monoclonal antibody.

- Received an investigational new drug within 28 days or 5 half-lives, whichever is
longer, prior to Screening.

- Received systemic corticosteroid therapy including budesonide (Tarpeyo/Kinpeygo) for
> 14 days within 12 weeks prior to Screening.

- Use of systemic immunosuppressant medications.

- Any confirmed or suspected immunosuppressive or immune-deficient state, including
but not limited to common variable immunodeficiency (CVID), HIV infection or
asplenia, history of bone marrow or organ transplantation with exception of corneal
transplants.

- Current severe infection requiring antimicrobials or history of recurrent, severe,
infections as determined by the Investigator.

- Positive serology test for hepatitis A virus IgM antibodies (anti-HAV IgM),
hepatitis B surface antigen (HBsAg), detectable hepatitis B virus (HBV) DNA,
hepatitis C virus (HCV) antibodies (participants who completed treatment and are
persistently antibody be allowed), or antibodies to HIV-1 and/or HIV-2 at Screening.

- Received a live vaccination within 12 weeks prior to Screening or plan to have a
live vaccination within 6 months after the last dose of study drug.

- History of malignancy unless cancer free for at least 5 years or non-melanoma skin
cancer that was completely resected. A participant with curatively treated cervical
carcinoma in situ is eligible for the study. Participants with low-risk prostate
cancer (i.e., Gleason score < 7 and prostate specific antigen < 10 ng/mL) are
allowed.

- Pregnancy or breastfeeding or intent to become pregnant or to donate sperm during
the study period and until 24 weeks after last dose.

- History or evidence of any other clinically significant disorder, condition,
disease, or laboratory finding that, in the Investigator's assessment, would place
the participant at unacceptable risk, limit compliance with study requirements, or
confound interpretation of study results.

- IgG levels < 6 g/L at Screening.

- Participation in another interventional trial with an investigational agent/device
is prohibited during the course of this study.

Novartis Investigative Site

Recruiting

La Plata,Buenos Aires,B1902cos,Argentina

Novartis Investigative Site

Recruiting

San Fernando del Valle de Catamarca,Catamarca,K4700,Argentina

Novartis Investigative Site

Recruiting

Barracas,Ciudad Autónoma De BuenosAires,C1280aeb,Argentina

Novartis Investigative Site

Recruiting

Rosario,Santa Fe,S2013dtc,Argentina

Novartis Investigative Site

Recruiting

Ciudad Autónoma de Buenos Aires,C1425,Argentina

Novartis Investigative Site

Recruiting

Santa Fe,S3000epv,Argentina

Novartis Investigative Site

Recruiting

Gosford,New South Wales,2250,Australia

Novartis Investigative Site

Recruiting

Kogarah,New South Wales,2217,Australia

Novartis Investigative Site

Recruiting

Liverpool,New South Wales,2170,Australia

Novartis Investigative Site

Recruiting

Penrith,New South Wales,2750,Australia

Novartis Investigative Site

Recruiting

Cairns North,Queensland,4870,Australia

Novartis Investigative Site

Recruiting

Box Hill,Victoria,3128,Australia

Novartis Investigative Site

Recruiting

St Albans,Victoria,3021,Australia

Novartis Investigative Site

Recruiting

Bonheiden,Antwerpen,2820,Belgium

Novartis Investigative Site

Recruiting

Gent,Oost-Vlaanderen,9000,Belgium

Novartis Investigative Site

Recruiting

Roeselare,West-Vlaanderen,8800,Belgium

Novartis Investigative Site

Recruiting

Liège,Liège,Belgium

Novartis Investigative Site

Recruiting

Lodelinsart,6042,Belgium

Novartis Investigative Site

Recruiting

Woluwe-Saint-Lambert,1200,Belgium

Novartis Investigative Site

Recruiting

São Paulo,04023-900,Brazil

Novartis Investigative Site

Recruiting

Santana,Amapá,68925-000,Brazil

Novartis Investigative Site

Recruiting

Belo Horizonte,Minas Gerais,30130-100,Brazil

Novartis Investigative Site

Recruiting

Porto Alegre,Rio Grande Do Sul,90035-074,Brazil

Novartis Investigative Site

Recruiting

Joinville,Santa Catarina,89227-680,Brazil

Novartis Investigative Site

Recruiting

São Bernardo Do Campo,São Paulo,09780-000,Brazil

Novartis Investigative Site

Recruiting

São Paulo,01323-001,Brazil

Novartis Investigative Site

Recruiting

Brampton,Ontario,L6t 0h9,Canada

Novartis Investigative Site

Recruiting

East York,Ontario,M4c 5t2,Canada

Novartis Investigative Site

Recruiting

London,Ontario,N6a 5a5,Canada

Novartis Investigative Site

Recruiting

Guangzhou,Guangdong,510080,China

Novartis Investigative Site

Recruiting

Biškupec Zelinski,10380,Croatia

Novartis Investigative Site

Recruiting

Rijeka,51000,Croatia

Novartis Investigative Site

Recruiting

Zagreb,Grad Zagreb,10000,Croatia

Novartis Investigative Site

Recruiting

Praha,Praha, Hlavní Mesto,128 08,Czechia

Novartis Investigative Site

Recruiting

Grenoble,38043,France

Novartis Investigative Site

Recruiting

Paris,75010,France

Novartis Investigative Site

Recruiting

Paris,75015,France

Novartis Investigative Site

Recruiting

Nîmes,Gard,30029,France

Novartis Investigative Site

Recruiting

Lille,Nord,59000,France

Novartis Investigative Site

Recruiting

Lyon,Rhône,69437,France

Novartis Investigative Site

Recruiting

Magdeburg,Sachsen-Anhalt,39120,Germany

Novartis Investigative Site

Recruiting

Jena,Thüringen,07747,Germany

Novartis Investigative Site

Recruiting

Essen,45147,Germany

Novartis Investigative Site

Recruiting

Hannover,Niedersachsen,30459,Germany

Novartis Investigative Site

Recruiting

Hannover,Niedersachsen,30625,Germany

Novartis Investigative Site

Recruiting

Mainz,Rheinland-Pfalz,55131,Germany

Novartis Investigative Site

Recruiting

Trier,Rheinland-Pfalz,54292,Germany

Novartis Investigative Site

Recruiting

Heralkion,71409,Greece

Novartis Investigative Site

Recruiting

Ioannina,450 01,Greece

Novartis Investigative Site

Recruiting

Ioannina,455 00,Greece

Novartis Investigative Site

Recruiting

Thessaloniki,546 29,Greece

Novartis Investigative Site

Recruiting

Patras,Achaïa,265 04,Greece

Novartis Investigative Site

Recruiting

Athens,Attiki,12462,Greece

Novartis Investigative Site

Recruiting

Kalamaria,Thessaloniki,551 34,Greece

Novartis Investigative Site

Recruiting

Lucknow,Uttar Pradesh,226005,India

Novartis Investigative Site

Recruiting

Dehradun,248001,India

Novartis Investigative Site

Recruiting

Hyderabad,Andhra Pradesh,500084,India

Novartis Investigative Site

Recruiting

Jaipur,Rajasthan,302001,India

Novartis Investigative Site

Recruiting

Be'er Sheva,HaDarom,84101,Israel

Novartis Investigative Site

Recruiting

Ramat Gan,Tel-Aviv,52394,Israel

Novartis Investigative Site

Recruiting

Be'er Ya'akov,70300,Israel

Novartis Investigative Site

Recruiting

Ramat Gan,5262100,Israel

Novartis Investigative Site

Recruiting

Tel-Aviv,64239,Israel

Novartis Investigative Site

Recruiting

Trieste,Friuli-Venezia Giulia,34149,Italy

Novartis Investigative Site

Recruiting

Roma,Lazio,00168,Italy

Novartis Investigative Site

Recruiting

Pavia,Lombardia,27100,Italy

Novartis Investigative Site

Recruiting

Ranica,Lombardia,24020,Italy

Novartis Investigative Site

Recruiting

Sapporo-shi,Hokkaidô,060-8604,Japan

Novartis Investigative Site

Recruiting

Yufu-Shi,Ôita,879-5503,Japan

Novartis Investigative Site

Recruiting

Hachioji-Shi,Tokyo,192-0071,Japan

Novartis Investigative Site

Recruiting

Kitakyushu,Hukuoka,802-8555,Japan

Novartis Investigative Site

Recruiting

Minato-Ku,Tokyo,105-8471,Japan

Novartis Investigative Site

Recruiting

Yokohama-Shi,Kanagawa,236-0004,Japan

Novartis Investigative Site

Recruiting

Shinjuku-Ku,Tokyo,162-0054,Japan

Novartis Investigative Site

Recruiting

Kashihara,Nara,634-8522,Japan

Novartis Investigative Site

Recruiting

Chiba,260-8712,Japan

Novartis Investigative Site

Recruiting

Nara-Shi,Nara,630-8581,Japan

Novartis Investigative Site

Recruiting

Kasugai-Shi,Aiti,486-0804,Japan

Novartis Investigative Site

Recruiting

Niigata,951-8520,Japan

Novartis Investigative Site

Recruiting

Urayasu-Shi,Tiba,279-0021,Japan

Novartis Investigative Site

Recruiting

Toyoake-shi,Aiti,470-1192,Japan

Novartis Investigative Site

Recruiting

Okayama,700-8558,Japan

Novartis Investigative Site

Recruiting

Bunkyo-Ku,Tokyo,113-8431,Japan

Novartis Investigative Site

Recruiting

Seodaemun-gu,Seoul Teugbyeolsi,03722,Korea, Republic of

Novartis Investigative Site

Recruiting

Seongbuk-Gu,Seoul Teugbyeolsi,02841,Korea, Republic of

Novartis Investigative Site

Recruiting

Guri-si,Gyeonggido,Korea, Republic of

Novartis Investigative Site

Recruiting

Dongan-Gu, Anyang-Si,Gyeonggido,14068,Korea, Republic of

Novartis Investigative Site

Recruiting

Daejeon,301721,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,06973,Korea, Republic of

Novartis Investigative Site

Recruiting

Uijeongbu-Si,Gyeonggido,11765,Korea, Republic of

Novartis Investigative Site

Recruiting

Jongno-gu,Seoul Teugbyeolsi,03080,Korea, Republic of

Novartis Investigative Site

Recruiting

Kajang,Selangor,43000,Malaysia

Novartis Investigative Site

Recruiting

Kuala Lumpur,WilayahPersekutuan KualaLumpur,50586,Malaysia

Novartis Investigative Site

Recruiting

Kuala Lumpur,WilayahPersekutuan KualaLumpur,59100,Malaysia

Novartis Investigative Site

Recruiting

Kuantan,Pahang,25100,Malaysia

Novartis Investigative Site

Recruiting

Sibu,Sarawak,96000,Malaysia

Novartis Investigative Site

Recruiting

Monterrey,64060,Mexico

Novartis Investigative Site

Recruiting

Chihuahua,Chiapas,31217,Mexico

Novartis Investigative Site

Recruiting

Oaxaca,Distrito Federal,68000,Mexico

Novartis Investigative Site

Recruiting

Aguascalientes,20259,Mexico

Novartis Investigative Site

Recruiting

Girona,17007,Spain

Novartis Investigative Site

Recruiting

Lleida,25198,Spain

Novartis Investigative Site

Recruiting

Taipei City,100,Taiwan

Novartis Investigative Site

Recruiting

Taipei city,116,Taiwan

Novartis Investigative Site

Recruiting

Kaohsiung,Taiwan

Novartis Investigative Site

Recruiting

Hualien City,970,Taiwan

Novartis Investigative Site

Recruiting

Bornova,Izmir,35100,Turkey

Novartis Investigative Site

Recruiting

İzmit,Kocaeli,41380,Turkey

Novartis Investigative Site

Recruiting

Kayseri,38039,Turkey

Novartis Investigative Site

Recruiting

Bristol,Bs10 5nb,United Kingdom

Dallas Renal Group - 1411 N Beckley Ave

Recruiting

Dallas,Texas,75230,United States

University of California, San Francisco

Recruiting

San Francisco,California,94143,United States

University of Cincinnati College of Medicine - 231 Albert Sabin Way

Recruiting

Cincinnati,Ohio,45267-2827,United States

University Of Iowa Hospitals And Clinics

Recruiting

Iowa City,Iowa,52242-1009,United States

Dallas Renal Group - Waxachie - 2460 N. I-35

Recruiting

Dallas,Texas,75237-3461,United States

University of Colorado Hospital

Recruiting

Aurora,Colorado,80045,United States

Cleveland Clinic-9500 Euclid Ave

Recruiting

Cleveland,Ohio,44109-1900,United States

University of Alabama at Birmingham: The Kirklin Clinic

Recruiting

Birmingham,Alabama,35233-1926,United States

Intermed Consultants

Recruiting

Edina,Minnesota,55435-2129,United States

DaVita Clinical Research

Recruiting

El Paso,Texas,79925,United States

Denver Nephrology Research Division

Recruiting

Denver,Colorado,80230-6441,United States

OHSU - Oregon Clinical and Translational Research Institute

Recruiting

Portland,Oregon,97239,United States

Nephrology Consultants, LLC

Recruiting

Huntsville,Alabama,35805-4104,United States

David Tietjen

DaVita Clinical Research

Recruiting

Minneapolis,Minnesota,55404,United States

University of Texas MD Anderson Cancer Center-1155 Pressler

Recruiting

Houston,Texas,77030-2348,United States

Vida Medical Centers - Pembroke Pines

Recruiting

Pembroke Pines,Florida,33023-2213,United States

Northeast Clinical Research Center, LLC

Recruiting

Bethlehem,Pennsylvania,18017-2159,United States

Kidney Disease Medical Group Inc-1500 S Central Ave

Recruiting

Glendale,California,91204-2530,United States

Capital District Renal Physicians

Recruiting

Clifton Park,New York,12065,United States

East Texas Nephrology Associates

Recruiting

Lufkin,Texas,75904-3132,United States

NorthShore University HealthSystem

Recruiting

Evanston,Illinois,60201-1700,United States

Columbia Nephrology Associates , P.A. - Columbia

Recruiting

Columbia,South Carolina,29203-6476,United States

IMD Clinical Trials

Recruiting

Huntington Park,California,90255-2733,United States

Nephrology Associates PC - Flushing

Recruiting

Flushing,New York,11355-5045,United States

Nephrology Associates of Northern Virginia-8501 Arlington Blvd

Recruiting

Fairfax,Virginia,22033-1907,United States

Nephrology Associales of Northern Illinois and Indiana

Recruiting

Hinsdale,Illinois,60521-3640,United States

Knoxville Kidney Center, PLLC - Frenova F1

Recruiting

Knoxville,Tennessee,37923,United States

Valiance Clinical Research

Recruiting

S. Gate,California,90280-5219,United States

Icahn School of Medicine at Mount Sinai

Recruiting

New York,New York,10029-6504,United States

Swedish Center for Comprehensive Care

Recruiting

Seattle,Washington,98104,United States

Nephrology Associates of Northern Illinois and Indiana - 7836 W Jefferson Blvd

Recruiting

Fort Wayne,Indiana,46804,United States

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals